Core Viewpoint - The report discusses the adjustments and initial grant related to the stock option incentive plan of Beijing Wandong Medical Technology Co., Ltd. for 2025, highlighting the approval process and compliance with relevant regulations [1][2][6]. Summary by Sections Definitions - The report defines key terms such as "incentive plan," "grant date," "exercise price," and "exercise conditions," which are essential for understanding the stock option incentive plan [1]. Approval Process - On March 20, 2025, the company's board of directors approved the draft of the stock option incentive plan and related management measures [3]. - The supervisory board also approved the plan on the same day, confirming the list of incentive objects [4]. - The plan was publicly announced from March 28 to April 8, 2025, with no objections raised by employees [4]. - The annual shareholders' meeting on April 16, 2025, approved the plan, granting the board the authority to manage related matters [4]. Adjustments to the Incentive Plan - On May 21, 2025, the board and supervisory board approved adjustments to the initial grant list, reducing the number of incentive objects from 87 to 85 and the total stock options from 10.8 million to 9.6 million [5][7]. - The exercise price was adjusted from 15.18 yuan to 15.05 yuan following the completion of the 2024 profit distribution [8]. Compliance and Fairness - The independent financial advisor confirmed that the adjustments and grants comply with the relevant regulations and do not harm the interests of shareholders [9][11]. - The report emphasizes that the conditions for granting stock options have been met, and the incentive objects are valid [7][11]. Financial Impact - The financial advisor suggests that the company should account for the costs associated with the stock option plan in accordance with accounting standards, noting potential dilution effects [11]. Conclusion - The independent financial advisor concludes that the adjustments and initial grants of the stock option incentive plan have received necessary approvals and comply with legal requirements, ensuring no detriment to the company or its shareholders [11].

Group 1 - The board of directors of Jiangsu Feiwo Tai Nano Technology Co., Ltd. held a temporary meeting on May 21, 2025, where all nine directors attended and the meeting complied with relevant laws and regulations [1][2] - The board approved the 2025 stock option incentive plan, granting 4,658,312 stock options to 15 eligible incentive objects, with the grant date set as May 21, 2025 [1][2] - The company aims to enhance operational quality and investor returns through its "Quality Improvement and Efficiency Enhancement Action Plan for 2025," reflecting confidence in future development and internal value [2]

北京万东医疗科技股份有限公司 监事会关于公司 2025 年股票期权激励计划首次授予激励对象 名单（授予日）的核查意见 北京万东医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》（以下简 称"《管理办法》"）等有关法律、法规及规范性文件和《北京万东医疗科技股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，对公司2025年股 票期权激励计划（以下简称"本次激励计划"）首次授予激励对象名单（授予日 ）进行审核，发表核查意见如下： 一、鉴于公司2名激励对象因离职原因，已不再满足成为公司2025年股票期权 激励对象的条件，所被授予的股票期权予以取消，根据公司 2024年年度股东大会 的授权，公司董事会对本次激励计划的首次授予激励对象名单及授予数量进行相 应调整；鉴于公司2024年年度利润分配已经实施完毕，2025年股票期权激励计划 首次授予的行权价格将相应调整。本次调整后，本次激励计划首次授予激励对象 人数由87人调整为85人，首次授予的股票期权数量由1,080 万份调整为960万份， 行权价格将由15.18元/份调整为15.05元 ...

证券代码：002311 证券简称：海大集团 公告编号：2025-026 广东海大集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广东海大集团股份有限公司（以下简称"公司""本公司"）于 2025 年 4 月 18 日召开第六届董事会第二十四次会议和第六届监事会第十九次会议，审议通过了 《关于公司 2021 年股票期权激励计划首次授予第四个行权期及预留授予第三个 《关于公司 2024 年股票期权 行权期不符合行权条件并注销相应股票期权的议案》 激励计划第一个行权期不符合行权条件并注销相应股票期权的议案》和《关于注 销公司 2021 年股票期权激励计划和 2024 年股票期权激励计划部分股票期权的议 ，确定公司 2021 年股票期权激励计划首次授予第四个行权期及预留授予第三 案》 个行权期不符合行权条件，同意注销相应股票期权 9,719,550 份；确定公司 2024 年股票期权激励计划第一个行权期不符合行权条件，同意注销相应股票期权 名激励对象对应的 467,490 份股票期权；同意注销 2024 年股票期权激励计划因 离职或解除劳动关系的 1 ...

Core Viewpoint - The company conducted a self-examination regarding the trading activities of insiders related to the 2025 stock option incentive plan, confirming no insider trading occurred during the self-examination period [1][2]. Group 1: Self-Examination Overview - The company held meetings on April 21, 2025, to review the draft of the 2025 stock option incentive plan and related proposals [1]. - The self-examination period covered the six months prior to the public disclosure of the incentive plan [1]. Group 2: Findings on Trading Activities - Five individuals involved in the self-examination were found to have traded the company's stock during the self-examination period, while others did not engage in any trading [2]. - The trading activities of the five individuals were based on their own analysis of the secondary market and were not influenced by any insider information regarding the incentive plan [2]. Group 3: Conclusion - The company concluded that there was no evidence of insider information leakage or insider trading related to the 2025 stock option incentive plan during the self-examination period [2].

Core Viewpoint - The legal opinion letter confirms that Huizhou Huayang Group Co., Ltd. has obtained the necessary approvals and authorizations for adjusting the exercise price of stock options under its 2021 stock option incentive plan, in compliance with relevant regulations and internal guidelines [4][8][9]. Group 1: Approval and Authorization - The adjustment of the exercise price for the 2021 incentive plan has been approved by the company's board and relevant committees, with independent directors and the supervisory board providing their consent [4][6][8]. - The necessary public disclosures were made, and no objections were received during the public notice period [4][8]. Group 2: Specifics of the Adjustment - The exercise price of the stock options has been adjusted from RMB 34.97 per share to RMB 34.49 per share, following the company's capital reserve conversion and dividend distribution [8]. - The adjustment is in accordance with the provisions of the 2021 incentive plan, which stipulates that the exercise price must be adjusted in the event of capital changes such as stock dividends or splits [8]. Group 3: Conclusion - The legal opinion concludes that the adjustment of the exercise price for the stock options is valid and complies with the 2021 incentive plan and relevant regulations [9].

Core Viewpoint - The company has approved an adjustment to the exercise price of the 2021 stock option incentive plan, reducing it from 34.97 RMB to 34.49 RMB per share due to a cash dividend distribution [5][6]. Summary by Sections Stock Option Incentive Plan - The company held meetings to review and approve the adjustment of the exercise price for the 2021 stock option incentive plan [1][4]. - The independent directors and the supervisory board provided their consent and verification regarding the adjustments made to the incentive plan [3][4]. Adjustment Details - The adjustment to the exercise price is calculated based on the cash dividend of 0.48 RMB per share, leading to the new exercise price of 34.49 RMB [5]. - The adjustment process complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [5][6]. Financial Impact - The adjustment of the exercise price is not expected to have a significant impact on the company's financial condition or operating results [5]. Legal Opinions - The legal opinion from Beijing Tongshang (Shenzhen) Law Firm confirms that the necessary approvals for the adjustment have been obtained and that it complies with the relevant regulations [6].

证券代码：605089 证券简称：味知香 公告编号：2025-026 苏州市味知香食品股份有限公司 买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证监会《上市公司股权激励管理办法》（以下简称《管理办法》）、 《上市公司信息披露管理办法》、 本公司于 2025 年 4 月 25 日召开第三届董事会第六次会议，审议通过了《关 于 <苏州市味知香食品股份有限公司 ensp="ensp" 年股票期权激励计划="年股票期权激励计划" 草案="草 案"> 及其摘 要的议案》及相关议案。根据《管理办法》的有关规定，公司对内幕信息知情人 《上海证券交易所上市公司信息披露事务管理制 度指引》等法律、法规及规范性文件的要求，苏州市味知香食品股份有限公司（以 下简称"公司"、"本公司"）遵循公司《信息披露管理制度》、 《内幕信息知情 人登记管理制度》的规定，针对公司 2025 年股票期权激励计划（草案） （以下简 称"激励计划"）采取了充分必要的保密措施，同时对激励计划的内幕信息知情 人做了必要登记。 买卖公司 ...

Core Viewpoint - The company has established a stock option incentive plan for 2025 to attract and retain talent, enhance team cohesion, and align the interests of shareholders, the company, and core teams for long-term development [10][11]. Summary by Sections Incentive Plan Overview - The stock option incentive plan will grant a total of 15.324 million stock options, accounting for approximately 4.83% of the company's total share capital as of the plan's announcement date [2][15]. - The initial grant will consist of 12.324 million options (3.88% of total shares), while 3 million options will be reserved (0.95% of total shares) [2][15]. Granting and Eligibility - The plan will involve 1,153 initial grantees, including directors, senior management, core management, and technical (business) backbones, excluding independent directors and major shareholders [3][13]. - The initial grant's exercise price is set at 29.04 RMB per option, with adjustments possible based on corporate actions [5][8]. Performance Targets - The performance targets for the stock options are based on net profit growth, with specific annual growth rates set for 2025 (20%), 2026 (40%), and 2027 (60%) relative to the 2024 net profit [5][29]. Management and Oversight - The company's shareholders' meeting will approve the plan, and the board of directors will manage its execution, with a compensation committee overseeing the process [11][12]. - The plan includes provisions for the adjustment of stock options and exercise prices in response to corporate actions such as stock splits or dividends [31][32]. Duration and Conditions - The plan's validity extends up to 48 months from the date of authorization, with specific waiting periods before options can be exercised [18][19]. - The exercise of options is contingent upon meeting both company-level performance targets and individual performance assessments [26][30]. Compliance and Restrictions - The plan ensures compliance with relevant laws and regulations, and it outlines conditions under which individuals may not participate in the incentive program [14][7]. - There are restrictions on the transfer of shares acquired through the incentive plan, particularly for directors and senior management [22].

证券代码：002315 证券简称：焦点科技 公告编号：2025-022 了《焦点科技股份有限公司 2025 年股票期权激励计划（草案）》 （以下简称"《股 票期权激励计划（草案）》"、"本激励计划"）及其摘要等相关议案，具体内 容详见公司于 2025 年 4 月 30 日在巨潮资讯网（www.cninfo.com.cn）上披露的 相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所上市公司自律监管指南第 1 号——业务办理》等法律、法规和规范 性文件的相关规定，公司对 2025 年股票期权激励计划（以下简称"激励计划"） 采取了充分必要的保密措施，并对激励计划的内幕信息知情人进行了必要的登记。 同时，公司通过向中国证券登记结算有限责任公司深圳分公司查询，对本激励计 划内幕信息知情人及激励对象在本股权激励计划草案公告前 6 个月内（即 2024 年 10 月 29 日至 2025 年 4 月 29 日，以下简称"自查期间"）买卖本公司股票及 其衍生品种的情况进行自查，具体情况如下： 焦点科技股份有限公司 关于 2025 年股票期权激励计划内幕信息知情人及激 励对象买卖公司 ...